EmphysemaNCT05204875
Functional Lung Imaging in Patients With Respiratory Compromise Undergoing Endobronchial Valve Placement
An observational study of Emphysema, run by Temple University at 1 site in United States.
Trial summary
Bronchoscopic lung volume reduction (BLVR) using endobronchial valves is effective in improving quality of life in patients suffering from emphysema. BLVR treatment in advanced emphysema requires targeted segmental or sub-segmental placement of endobronchial valves (EBV) to achieve total lobar occlusion to induce… Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Emphysema
- What is being tested?
- X-ray Velocimetry
- Type of treatment
- Surgery or procedure
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Jul 2022to Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with COPD undergoing bronchoscopic lung volume reduction
Who may be able to join
- Emphysema
- Undergoing evaluation and planned treatment with BLVR
- Adults, 40 years of age and older
- Consents to functional lung imaging evaluation
- Access to previous chest CT as part of the clinical workup for BLVR
Who cannot join
- Known contraindication to BLVR
- Currently receiving mechanical ventilation, intensive or other critical care
- Pregnant women
- Contraindication to ionizing radiation
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Temple University Hospital
Philadelphia, Pennsylvania, 19140
Michael Jacobs, PharmD, 215-707-2242, michael.jacobs@tuhs.temple.edi
Francine McGonagle, RN, 215-707-2682, francine.mcgonagle@tuhs.temple.edu
About this study
Bronchoscopic lung volume reduction (BLVR) using endobronchial valves is effective in improving quality of life in patients suffering from emphysema. BLVR treatment in advanced emphysema requires targeted segmental or sub-segmental placement of endobronchial valves (EBV) to achieve total lobar occlusion to induce effective lobar volume reduction. BLVR procedure success rate declines in patients with incomplete lobar fissure integrity due to the potential for collateral ventilation to circumvent EBV lobar occlusion. Current methods that assess lobar collateral ventilation as a correlate of fissure integrity are imperfect, resulting in a significant percentage of patients having equivocal assessment, leading to suboptimal selection of patients and potential for inappropriate selection of patients for BLVR. Additionally, methods used to select the target lobe for EBV placement predominately rely on the extent of emphysematous destruction. There is also a need to select based on the extent of physiological disturbance at the lobar level. Distribution of ventilation or regional ventilation heterogeneity may be associated with collateral ventilation. Therefore, in this study we wish to quantify lobar distribution of ventilation and ventilation heterogeneity in patients undergoing investigation for BLVR to determine the additive contribution of functional lung imaging for assessing lobar physiological derangement and suitability for EBV treatment.
Read the detailed description
Approach: A novel functional lung imaging, X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing. Specific measurements of lobar volume at end inspiration, expiration and the tidal breathing changes, inspiratory and expiratory lobar flow and estimation of airway flow resistance using x-ray velocimetry. These variables will be used to explore indices related to collateral ventilation by comparing time-volume changes based on segmentation and differential residual. The performance of XV has been assessed in cohort and case series of patients undergoing therapy for cancer, demonstrating changes in ventilation distribution and heterogeneity. The objective of the current investigation is to determine whether XV technology can assist in determining lobar selection, indicators of success, or response-related clinical outcomes with BLVR.
Scope: Examine ventilation distribution and heterogeneity using XV functional lung imaging analysis in moderate to severe COPD undergoing evaluation for BLVR.
Aims: 1) Assess the applicability of XV ventilation distribution and heterogeneity for BLVR candidate screening compared to conventional tools of quantitative HRCT and ventilation perfusion scanning.
- Identify characteristics of lobar ventilation distribution and ventilation heterogeneity in candidates being assessed for BLVR.
- Determine whether if there is an association between functional lung imaging data and clinical status (6MWD, St George's Questionnaire, CAT, mMRC (Modified Medical Research Council) Dyspnea Scale).
Study Design:
- Participant Recruitment This is an adaptive trial design in 10 patients in consecutive recruitment at Temple University Hospital. As subsequent sites initiate investigation, a small number of roll-in study participants (n=2) will be enrolled for site validation. Patient managed by Temple University Hospital with inclusion criteria will be identified by Dr. Gerard Criner for possible inclusion in this study. A waiver for informed consent will be obtained to allow review of their medical records to determine if these patients may be eligible for study inclusion. It is anticipated that most of these patients will have known underlying lung disease. The patient will be screened by the principal investigator or designee for eligibility. Upon meeting all eligibility criteria, the patient will be approached by the principal investigator or designee to obtain informed consent for inclusion into the study. Discussion of the study will take place in a private room and will include the relevance of this study, risks they may encounter, data collected, and the protection of their personal information.
All those included in the study will have a diagnosis consistent with existing or potential clinical work up for BLVR procedure. As this is a cross-sectional study subjects will not be randomized. The study timeframe for participation will be defined as the time beginning from recruitment for participation in functional lung imaging which is adjunct measurement to an existing clinical procedure, until the collection of all data associated with the study. Data may be collected from medical records whilst the study is approved by the IRB. The clinical course will neither depend upon, be altered by nor rely on any of the research data collected as part of this study. To examine the relationship of study data with standard of care, clinical status, disease exacerbation, prior history of hospitalization, the data collection period will include historical health records and lung health records before and after the functional lung imaging scan
- Conditions
- Emphysema
- Being tested
- X-ray Velocimetry
- Medical subject headings
- Emphysema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
X-ray VelocimetryRadiation
X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
| Study group | Role | What they receive |
|---|---|---|
| Functional lung imaging | Assess the applicability of XV ventilation distribution and heterogeneity for BLVR candidate screening compared to conventional tools of quantitative HRCT and ventilation perfusion scanning. Receives: Radiation: X-ray Velocimetry |
What is being measured
The primary outcome is the main question the study is designed to answer.
The objective of the current investigation is to determine whether XV technology can assist in determining lobar selection, indicators of success, or response-related clinical outcomes with BLVR.
Functional lung imaging analysis in endobronchial valve placement
Measured: functional lung imaging and software analysis will be available after the procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jan 2022
- Study start5 Jul 2022
- Primary completionNov 2023 (estimated)
- Study completionDec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EmphysemaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Temple University
- Sponsor type
- University, hospital or other
- Collaborators
- Respiratory Compromise Institute
- Responsible party
- Sponsor
- Investigators
- Gerard Criner, MD, Principal investigator, Temple University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05204875
- Sponsor's protocol ID
- 269649
- Status last verified
- Oct 2022
- First submitted
- 22 Dec 2021
- Last updated
- 24 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Functional Lung Imaging in Patients With Respiratory Compromise Undergoing Endobronchial Valve Placement
- ClinicalTrials.gov ID
- NCT05204875
- Acronym / sponsor ID
- 269649
- Conditions
- Emphysema
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Temple UniversityUniversity, hospital or other
- Collaborators
- Respiratory Compromise Institute
- Study start
- 5 Jul 2022 (actual)
- Primary completion
- Nov 2023 (estimated)
- Study completion
- Dec 2023 (estimated)
- First posted
- 24 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Bronchoscopic lung volume reduction (BLVR) using endobronchial valves is effective in improving quality of life in patients suffering from emphysema. BLVR treatment in advanced emphysema requires targeted segmental or sub-segmental placement of endobronchial valves (EBV) to achieve total lobar occlusion to induce effective lobar volume reduction. BLVR procedure success rate declines in patients with incomplete lobar fissure integrity due to the potential for collateral ventilation to circumvent EBV lobar occlusion. Current methods that assess lobar collateral ventilation as a correlate of fissure integrity are imperfect, resulting in a significant percentage of patients having equivocal assessment, leading to suboptimal selection of patients and potential for inappropriate selection of patients for BLVR. Additionally, methods used to select the target lobe for EBV placement predominately rely on the extent of emphysematous destruction. There is also a need to select based on the extent of physiological disturbance at the lobar level. Distribution of ventilation or regional ventilation heterogeneity may be associated with collateral ventilation. Therefore, in this study we wish to quantify lobar distribution of ventilation and ventilation heterogeneity in patients undergoing investigation for BLVR to determine the additive contribution of functional lung imaging for assessing lobar physiological derangement and suitability for EBV treatment.
Detailed description
Approach: A novel functional lung imaging, X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing. Specific measurements of lobar volume at end inspiration, expiration and the tidal breathing changes, inspiratory and expiratory lobar flow and estimation of airway flow resistance using x-ray velocimetry. These variables will be used to explore indices related to collateral ventilation by comparing time-volume changes based on segmentation and differential residual. The performance of XV has been assessed in cohort and case series of patients undergoing therapy for cancer, demonstrating changes in ventilation distribution and heterogeneity. The objective of the current investigation is to determine whether XV technology can assist in determining lobar selection, indicators of success, or response-related clinical outcomes with BLVR.
Scope: Examine ventilation distribution and heterogeneity using XV functional lung imaging analysis in moderate to severe COPD undergoing evaluation for BLVR.
Aims: 1) Assess the applicability of XV ventilation distribution and heterogeneity for BLVR candidate screening compared to conventional tools of quantitative HRCT and ventilation perfusion scanning.
- Identify characteristics of lobar ventilation distribution and ventilation heterogeneity in candidates being assessed for BLVR.
- Determine whether if there is an association between functional lung imaging data and clinical status (6MWD, St George's Questionnaire, CAT, mMRC (Modified Medical Research Council) Dyspnea Scale).
Study Design:
- Participant Recruitment This is an adaptive trial design in 10 patients in consecutive recruitment at Temple University Hospital. As subsequent sites initiate investigation, a small number of roll-in study participants (n=2) will be enrolled for site validation. Patient managed by Temple University Hospital with inclusion criteria will be identified by Dr. Gerard Criner for possible inclusion in this study. A waiver for informed consent will be obtained to allow review of their medical records to determine if these patients may be eligible for study inclusion. It is anticipated that most of these patients will have known underlying lung disease. The patient will be screened by the principal investigator or designee for eligibility. Upon meeting all eligibility criteria, the patient will be approached by the principal investigator or designee to obtain informed consent for inclusion into the study. Discussion of the study will take place in a private room and will include the relevance of this study, risks they may encounter, data collected, and the protection of their personal information.
All those included in the study will have a diagnosis consistent with existing or potential clinical work up for BLVR procedure. As this is a cross-sectional study subjects will not be randomized. The study timeframe for participation will be defined as the time beginning from recruitment for participation in functional lung imaging which is adjunct measurement to an existing clinical procedure, until the collection of all data associated with the study. Data may be collected from medical records whilst the study is approved by the IRB. The clinical course will neither depend upon, be altered by nor rely on any of the research data collected as part of this study. To examine the relationship of study data with standard of care, clinical status, disease exacerbation, prior history of hospitalization, the data collection period will include historical health records and lung health records before and after the functional lung imaging scan
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Functional lung imaging | – | Radiation: X-ray VelocimetryAssess the applicability of XV ventilation distribution and heterogeneity for BLVR candidate screening compared to conventional tools of quantitative HRCT and ventilation perfusion scanning. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with COPD undergoing bronchoscopic lung volume reduction
Key inclusion criteria (5 listed)
- Emphysema
- Undergoing evaluation and planned treatment with BLVR
- Adults, 40 years of age and older
- Consents to functional lung imaging evaluation
- Access to previous chest CT as part of the clinical workup for BLVR
Key exclusion criteria (4 listed)
- Known contraindication to BLVR
- Currently receiving mechanical ventilation, intensive or other critical care
- Pregnant women
- Contraindication to ionizing radiation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| X-ray VelocimetryX-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing. | Radiation | Functional lung imaging |
Primary outcome
The objective of the current investigation is to determine whether XV technology can assist in determining lobar selection, indicators of success, or response-related clinical outcomes with BLVR.
Time frame: functional lung imaging and software analysis will be available after the procedure
Functional lung imaging analysis in endobronchial valve placement
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Oct 2022.
Related trials for Emphysema
RecruitingEarly Phase 1
Xenon MRI to Evaluate Changes to Lung Function Following Bronchoscopic Treatment of Air Trapping in Emphysema
Air Trapping, Emphysema
RecruitingPhase 3
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
Alpha 1 Antitrypsin Deficiency
RecruitingObservational study
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Chronic Obstructive Pulmonary Disease (COPD), Smoking
RecruitingPhase 1
A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
Alpha 1 Antitrypsin Deficiency
Active, not recruitingObservational study
Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive, Emphysema
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gerard Criner, MD principal investigator
Temple University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Emphysema, run by Temple University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Gerard Criner, MD (215-707-8113, Gerard.criner@tuhs.temple.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The objective of the current investigation is to determine whether XV technology can assist in determining lobar selection, indicators of success, or response-related clinical outcomes with BLVR. (time frame: functional lung imaging and software analysis will be available after the procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Oct 2022; AzTrials last refreshed its copy on 1 Nov 2026.